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Abstract 
Introduction:  The prevalence of obesity has been increasing in the United States. We set out 
to investigate the use of anti-obesity drugs in recent years. 
Methods:  We included 2630 men, and 2702 women who took part in NHANES.   We 
analyzed their demographic, and anthropometric data, and their weight, and drug history.  A 
person is a candidate for treatment of obesity if the initial body mass index ≥ 30 kg/m2, or ≥ 
27 kg/m2 in the presence of other risk factors (e.g. hypertension, diabetes or dyslipidemia). 
Sampling weights were used to adjust for non-response bias, and the oversampling of blacks, 
Mexican Americans, and the elderly.  
Results:  45.9% of men, and 45.0% of women were candidates for treatment. Among these 
participants, 85.1% considered themselves overweight, 90.1% would like to lose weight, 
61.9% had dietary changes, 36.5% exercised, 3.7% took non-prescription diet pills and 2.2% 
took prescription diet pills to control weight during the preceding year.  During the preceding 
month, 0.5%, and 0.1% of participants were taking phentermine, and orlistat respectively. 
There were no participants on sibutramine.  
Conclusions:  Obesity is highly prevalent in the United States, but only a very small 
percentage is on anti-obesity medication. The withdrawal of sibutramine in October 2010 
would have minimal impact on the general population. While improvements in 
pharmacological treatment of obesity are needed, our study also revealed that there is a need 
for more lifestyle changes in the majority of obese individuals.  
Introduction 
Obesity is an epidemic world wide.  The prevalence of obesity is accelerating in developed 
and developing countries.   Studies have established that overweight, and obese people are at 
a higher risk of developing conditions like hypertension, dyslipidemia, type 2 diabetes, 
cardiovascular diseases, and obstructive sleep apnea 1-3.  Obesity is also a known risk factor 
for a variety of more health conditions including cancer and reproductive abnormalities 4.  In 
the United States (US), approximately 300,000 people die annually due to obesity related 
causes.  The morbidities associated with obesity accounts for a substantial amount of the 
national healthcare expenditure in US. Therefore it is time that obesity is accepted as a 
chronic disease and treatment directed towards achieving a sustainable, and healthy body 
weight 5. 
 
Lifestyle changes are an indispensible component in the treatment of obesity.  A combination 
of dietary changes and exercise has shown to be more effective in achieving greater long term 
weight loss6.  A recent study showed that a substantial proportion of obese Americans 
engaged in either diet changes or physical activities (73.5% women, and 60.3% men) but few 
adopted both 7.  Diet changes, and exercise are mainly short term remedies, and weight regain 
after one year of intervention is frequent8.  On the other hand, environmental, and genetic 
factors make some people gain weight more easily than others 9,10.  Modern technologies that 
help people to perform daily tasks with less effort, central heating, sedentary jobs, are factors 
contributing to obesity10. As they cannot be changed easily, losing weight is difficult. The 
American College of Physicians recommends pharmacological therapy for people with a 
body mass index (BMI) >30 kg/m2 or those with a BMI >27 kg/m2, and associated co-
morbidities 5,11. 
 
Use of anti-obesity drug therapy alone causes only a modest weight loss (<5kg), although this 
change has been shown to improve cardiovascular risk factors, like insulin sensitivity, 
glycemic control, dyslipidemia, and hypertension in overweight patients 12. Lifestyle changes 
including dietary changes, exercise, and behavioral therapy, enhances the effect of drug 
treatment 13. Therefore, the patient on anti-obesity drug should continue lifestyle changes.  
Accordingly, we analysed the use of pharmacological and non-pharmacological therapy for 
the treatment of obesity in the National Health and Nutrition Examination Survey (NHANES) 
study population. 
 
Methods and procedures 
The NHANES was initiated in 1960 with the intention of assessing the heath, and nutritional 
status of adults and children in US.  After 1999, NHANES became a continuous study 
focusing on a variety of health and nutritional needs that concerns the US population.  The 
methodology of this study, and the results are available online14.  International Review Board 
Approval was obtained from the NCHS Research Ethics Review Board (ERB) as a 
continuation of protocol # 2005-06. 
 
A total of 5332 (2630 men, and 2702 women) subjects in NHANES 2007-2008 were 
included in this analysis. Participants aged ≥20 years, who were non-pregnant, and had valid 
data on BMI, and self-reported history of hypertension, diabetes, and hypercholesterolemia 
were included.  Data extracted from the data set included demographic data such as age, 
gender, race/ethnicity, BMI, and self-reported history of weight, prescription medication, 
hypertension, hypercholesterolemia, and diabetes.   
 
Obesity was defined as BMI > 30.0 kg/m2 15.  Sibutramine, orlistat, and phentermine were 
considered as drugs for the treatment of obesity.  Candidates eligible for anti-obesity drugs 
were defined as participants with BMI>30.0 kg/m2 or BMI>27.0 kg/m2 in the presence of one 
or more risk factors (hypertension, diabetes or dyslipidemia)16-18.  Participants who were told 
by a health professional to have high blood pressure were defined as having hypertension. 
Similarly, those who were told to have high blood cholesterol and diabetes were defined as 
having hypercholesterolemia, and diabetes respectively.   
 
Weight control was defined as participants who took measures to reduce weight, stop gaining 
weight or both.  Dietary changes included eating less food, switching to low calorie foods, 
eating less fat, eating fewer carbohydrates, eating less sugar, candy & sweets, eating more 
fruits, vegetables, and salads, drinking a lot of water, having liquid diets, eating diet foods,  
following a special diet, changing eating habits, and skipping meals.  
 
Data was analysed using SPSS version 18 (SPSS Inc, Chicago, IL), and data was stratified 
mainly according to the eligibility of participants for treatment with anti-obesity drugs, and 
gender.  Participants with BMI >30.0 kg/m2 and those with BMI between 27.0 and 29.9 
kg/m2 with risk factors were taken as the two categories eligible for anti-obesity drug 
treatment. Sampling weights were used to adjust for non-response bias and the oversampling 
of blacks, Mexican Americans, and the elderly.  
 
Results 
Two categories, people with BMI >30.0 kg/m2 (obese), and those with both BMI 27.0-29.9 
kg/m2, and risk factors were identified as candidates for anti-obesity drug treatment (Table 1 
).  Among all people 34.3%, and 11.1% were obese and had BMI 27.0-29.0 kg/m2 with risk 
factors respectively (Table 1).  A total of 46.0% men, and 44.9% women were candidates to 
be treated with anti-obesity drugs.  The highest prevalence of subjects with BMI 27.0-29.9 
kg/m2, and risk factors were among the subjects aged ≥60 years for both men, and women.  
The overall prevalence of obesity was highest in subjects aged 40-59 years, especially in 
women.  Past studies have established that there is racial/ethnic difference in the prevalence 
of obesity13.  Non-Hispanic blacks showed the highest prevalence of obesity (44.1%), 
followed by Mexican Americans (39.3%), Non-Hispanic Whites (32.8), and others (26.9).  
Similar trends were found in both men, and women, but there was a trend of higher 
prevalence of obesity in women than in men among all ethnic groups.  In contrast, the 
prevalence of people with BMI 27.0-29.9 kg/m2, and risk factors was higher in non-Hispanic 
whites than that in non-Hispanic blacks (p = 0.013), especially in men (p<0.001).  
 
Table 2 shows the characteristics of candidates eligible for anti-obesity drugs.  Obese people 
were younger (47.8 years) than people with BMI 27.0-29.9 kg/m2, and risk factors (56.1 
years).  The majority of the obese people were within the ages 20-59 while people with BMI 
27.0-29.0 kg/m2 with risk factors were above 40 years.  Among the candidates for anti-
obesity drug treatment, majority were non-Hispanic whites.  More than 50% of the obese 
people had been told by a healthcare professional to have one or more risk factors.  There was 
a higher prevalence of hypertension (42.6%), and diabetes (35.9%) compared to 
hypercholesteremia (15.8%) in obese people.  The same trend was evident in people having 
BMI 27.0 -29.9 kg/m2 with one or more risk factors. 
 
Figure 1 shows the data on the self-reported weight history among people who were eligible 
for anti-obesity drugs.  The majority (85.1%) were aware that they were overweight.  90.1% 
of them desired to weigh less.  Only 61.9%, and 60.3 % of obese people, and people with 
BMI 27.0-29.9 kg/m2 with risk factors changed their diet to control weight during the 
preceding 12 months respectively (Figure 2).  An even lower percentage of people engaged in 
exercise to control weight in both categories during the preceding 12 months.  A 
comparatively lower percentage of subjects used methods such as taking prescription diet 
pills (2.2%), and non-prescription diet pills (3.7%) to control weight during the preceding 
year. Interestingly, a significantly higher number of women were engaged in diet changes, 
taking prescription and non prescription drugs, and other methods to control weight than 
men.   
 
Analysis of the prescription medication data shows that only 0.6% of eligible people were on 
anti-obesity drug treatment (Table 3).  Surprisingly, majority of them were on phentermine, 
followed by orlistat. There were no subjects on sibutramine which was withdrawn by the 
Food and Drug Administration (FDA) in October 2010. 
 
Discussion 
Our study reports the use of pharmacological and non-pharmacological therapy in the 
treatment of obesity among US adults in recent years.  It is evident that the majority of 
American men and women are candidates for anti-obesity drug treatment. However, an 
important finding of this study was that very few of these candidates were on medication for 
obesity; the use of prescription or non-prescription medications were disappointingly low.  
 
Given that sibutramine and orlistat were the drugs of choice for the treatment of obesity in 
2007-08, it was interesting to find that the majority of candidates were on phentermine 
followed by orlistat. Although phentermine is the most widely prescribed and cheapest anti-
obesity drug in the US19, its use is obsolete in some parts of the world due to its adrenergic 
responses resulting in increasing blood pressure and heart rate20,21.  In fact, phentermine is 
recommended only for short term use, and therefore of limited use in long term weight 
management18. It is of interest to note that none of the participants were on sibutramine. This 
drug was withdrawn in October 2010 as a result of the findings of the SCOUT study, which 
revealed that subjects with pre-existing cardiovascular conditions on long term sibutramine 
may have an increased risk of developing non-fatal myocardial infarction or non-fatal stroke 
22.  Even though the decision to withdraw sibutramine was controversial, it is reassuring to 
find that only a very small proportion of obese individuals would have been exposed to the 
alleged risks of sibutramine in the US.  Presently orlistat is the only choice for the 
pharmacologic treatment of obesity.  Its efficacy has been established in previous studies.20,23 
In practice, orlistat is not widely used, despite the fact that it is also available over the counter. 
This may be attributable to its unpleasant side effects19.  There is clearly a need for new and 
effective drugs for the treatment of obesity. However, these new treatments need careful 
evaluation of their risks and benefits. 
 
It was encouraging that the majority of candidates for anti-obesity drug treatment perceived 
themselves overweight, particularly as self perception of overweight is known to be a strong 
predictor to pursue weight control activities7. A large percentage of these candidates desired 
to lose weight indicating the need for a sustainable weight control plan.   
 
Non-pharmacologic interventions are an integral component in a weight control plan.  
However, adherence to lifestyle changes was low, and engaging in exercise seemed less 
popular than dietary changes among this sub-population. Another study using NHANES 1988 
– 2006 data showed that the proportion of participants engaging in physical activity 12 times 
a month or more has decreased from 53% to 43%, and eating 5 or more fruits and vegetables 
a day has decreased from 42% to 26% 24.  Poor adherence to lifestyle changes may be a result 
of unawareness of its importance among subjects, reluctance to change or in some cases 
discouragement by the futility of weight control efforts.  
 
There are some limitations in our study. The estimates of the percentage of anti-obesity drug 
treatment may be inaccurate due to the small number of participants on anti-obesity drugs. 
Nevertheless, this is in itself evidence for the under treatment of obesity.  
 
Conclusions 
Obesity is highly prevalent in the United States, but only a very small percentage is on anti-
obesity medication. Finding that none of the subjects were on sibutramine shows that its 
withdrawal in October 2010, would have minimal impact on the general population. While 
improvements in pharmacological treatment of obesity are needed, our study also revealed 
that there is a need for more lifestyle changes in the majority of obese individuals.  
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Figure 1: Weight perceptions and desire to lose weight among participants who were eligible 
for anti-obesity drug treatment  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2: Methods used to control weight. 
 
* indicates p value <0.05 for differences between men and women 
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 Table 1: Prevalence of obesity and subjects with both BMI 27.0 -29.9 kg/m2 and risk factors 
† indicates p value <0.05 for the prevalence between men and women 
 
 
 
 Prevalence of  subjects with BMI 
≥30.0 kg/m2 (obesity), % (SE) 
Prevalence of subjects with BMI 27.0 -29.9 
kg/m2 and  risk factors, % (SE) 
 All Men  Women All Men  Women 
N 5332 2630 2702 5332 2630 2702 
Overall 34.3(1.2) 32.8(1.6) 35.8(1.1) 11.1(0.6) 13.1(1.0) † 9.2(0.7) † 
Age group, 
year 
      
20 – 39 31.5(2.1) 28.5(2.0)† 34.7(2.6)† 3.7(0.7) 4.1(1.0) 3.2(0.6) 
40 – 59 36.4(1.8) 34.7(2.5) 38.1(2.2) 12.8(0.9) 17.5(1.8)† 8.3(0.8)† 
≥60 35.3 (1.1) 37.3 (2.0) 33.7 (1.8) 19.7(1.3) 21.2(1.5) 18.5(2.1) 
Race/ethni
city 
      
Non-
Hispanic 
white 
33.2(1.8) 33.1 (2.1) 33.3 (1.7) 12.4(0.8) 15.4(1.2)† 9.6(1.1)† 
Non-
Hispanic 
black  
44.1 (2.2) 37.4 (2.8)† 49.5 (2.1)† 9.3(0.8) 7.5(1.0)† 10.9(0.9)† 
Mexican 
American 
39.7 (3.7) 36.0 (4.4)† 44.3 (3.2)† 5.8(0.4) 6.0(0.8) 5.6(0.9) 
Others 27.6 (3.4) 24.4 (3.9) 30.9 (3.7) 8.5(1.6) 10.1(2.5) 6.9(1.6) 
 Table 2: Characteristics of candidates for anti-obesity drugs among participants 
  Participants with BMI >30.0 
kg/m2 (obesity) 
Participants with BMI of 27.0-29.9 
kg/m2and  risk factors 
N 1983 614 
Age, year 47.8(0.5) 56.1(0.6) 
Age group, %   
20 – 39 year 33.5 (1.8) 12.0(1.9) 
40 – 59 year 42.0 (1.6) 45.7(2.9) 
≥60 year  24.5 (1.2) 42.3(2.6) 
BMI, kg/m2 35.7(0.1) 28.5(0.05) 
Race/ethnicity, %   
Non Hispanic white 67.7 (5.0)  78.2(3.2) 
Non Hispanic black  14.4 (3.0)  9.5(2.2) 
Mexican American 9.4 (2.4)  4.2(0.8) 
Other  8.5 (1.8)  8.1(1.7) 
Risk Factors, %   
Diabetes 35.9 (1.3) 63.7 (2.2) 
Hypertension 42.6(1.5) 68.3 (1.9) 
Hypercholesterolemia 15.8 (1.7) 10.7 (0.9) 
Any of the above 57.7 (1.1) 100 (0.0) 
Data are expressed as mean or percent (SE). 
 
 
 
 
  
Table 3:  Anti-obesity drug treatment in obese and subjects with BMI 27.0 -29.9 kg/m2 with  risk 
factors  
 
Anti-obesity drug 
treatment 
All  (n=2597) Participants with 
BMI ≥30.0 
kg/m2(obesity) 
(n=1983) 
Participants with BMI of 
27.0-29.9 kg/m2and risk 
factors (n=614) 
 cases %(SE) cases %(SE) cases %(SE) 
Sibutramine 0 0.0 (0.0)* 0 0.0 (0.0)* 0 0.0 (0.0)* 
Orlistat 1 0.1 (0.1)* 1 0.1 (0.1)* 0 0.0 (0.0)* 
Phentamine 
Total 
9 
10 
0.5 (0.1)* 
0.6 (0.2)* 
9 
10 
0.4 (0.1)* 
0.6 (0.2)* 
1 
1 
0.3 (0.2)* 
0.3 (0.2)* 
*Estimates are unreliable due to coefficient of variation >0.3
